《慢性乙型肝炎患者管理英文版课件》由会员分享，可在线阅读，更多相关《慢性乙型肝炎患者管理英文版课件（44页珍藏版）》请在金锄头文库上搜索。
1、1RoadmapforManagementofPatientswithChronicHepatitisB(CHB)Prof.XinxinZhangRuiJinHospitalJiaoTongUniversityIntroductionPresentationObjectivesDataReview:AssociationsofHBVDNAwithOutcomesi.Naturalhistorystudiesii.ImpactoftreatmentKeyroleofHBVDNAinOn-TreatmentManagementi.TimingandmagnitudeofHBVDNAsuppress
2、ionOn-TreatmentRoadmapConceptSummaryandConclusionsContents2IntroductionTreatmentchallengeshighlightneedfornewmanagementapproachTreatinghepatitisBvirus(HBV)infectioncontinuestobeachallengeforphysiciansduetoComplicationsarisingfromchronicHBV(CHB)TheincreasingnumberofavailabletherapeuticoptionsTreatmen
3、tguidelinesrecognizetheimportanceofmonitoringandevaluationoftreatmentresponse;however,astandardon-treatmentmanagementapproachdoesnotexistToestablishanewtreatmentparadigm,weshouldaskDoeslong-termsuppressionofHBVreplicationachievethegoalsoftreatmentinCHB?Canthedegreeofon-treatmentviralsuppressionpredi
4、ctoutcomes?Doesprofound,earlyviralsuppressionatweek24predictclinicaloutcomes?CanaRoadmapconcepthelpachievethegoalsoftreatmentinCHB?3PresentationObjectivesToexploretheassociationbetweenpersistentviraemiaandhepatitisdiseaseprogressionToassesstherelationshipbetweenthedegreeofviralsuppressionandclinical
5、outcomeToassesstheroleofearlyandeffectiveviralloadreductionandtheassociationwithclinicaloutcomes*Toreviewanon-treatmentmanagementstrategytheroadmapconceptthatmayofferavaluableopportunityforenhancedtreatmentresponse* For safety information on the products referred to, please refer to the Product Info
6、rmation.45DataReview:AssociationsofHBVDNAwithOutcomesi.NaturalhistorystudiesCorrelationBetweenHBVDNAandHistologicActivityIndex(HAI)inUntreatedPatientsReviewof26prospectiveclinicaltrialsfoundastatisticallysignificantcorrelationbetweenviralloadlevelandhistologicalgrading246810120024681012BaselineHBVDN
7、Alevel,log10copies/mLr=0.78;P=0.0001HAIatbaselineMommeja-Marinetal200362.51.41.05.66.5P1,000,00010,000999,99910009999300999300HBVDNAatentry,copies/mL:Cirrhosis:AssociationwithBaselineHBVDNATaiwannaturalhistorystudyIloejeetal20067HepatocellularCarcinoma(HCC)AssociationwithbaselineHBVDNA:Taiwannatural
8、historystudyCumulativeincidenceofHCC,%HBVDNAatbaseline,copies/mLHBsAg-positive,untreatedparticipants(n=3,653)Chenetal20061068EvidenceforAssociationBetweenHBVDNAandClinicalOutcomesNaturalhistorystudiesdemonstrateLowerHBVDNAlevelsareassociatedwithbetterunderlyinghistologyHighHBVDNAmaybeanindependentpr
9、edictorforcirrhosisandHCCSustainedsuppressionofHBVmayreducelong-termriskofcirrhosisandHCCHypothesisneedstobeprovenprospectively910DataReview:AssociationsofHBVDNAwithOutcomesii.ImpactoftreatmentConsistentrelationshipintreatedanduntreatedpatientsHBVDNAcouldbeusedasamarkerofefficacyMedianHBVDNAleveldec
10、reasefrombaseline,log10copies/mLHAIimprovementfrombaseliner=0.96;P0.0000031234521012345Mommeja-Marinetal2003CorrelationBetweenHBVDNAandHistologicActivityIndex(HAI)inTreatedPatients11P0.001HBVDNAatweek72,copies/mLHBeAg-negativepatients(n=537)treatedwithlamivudine,peg-interferonalfa-2a,orbothcombinedf
11、or48weeksPatientswithhistologicalresponseatweek72,%Marcellinetal2004ViralSuppressionatWeek72isAssociatedwithHistologicImprovement105/329116/20812Months051015202506121824303613%21%5%Liaw2005Patientswithdiseaseprogression,%ViralSuppressionSignificantlyImpactsDiseaseProgressionLamivudineWildtypeLamivud
12、ineYMDDmPlaceboHBeAg-positivepatients(n=651)treatedwithlamivudineorplacebo13ViralSuppressionImprovesOutcomesStudiesreportingassociationswithoutcomesOutcomeCitation(s)Improvedclinicaloutcomesafterresponsetointerferonalfa(HBeAg+orHBeAg-)Niederauetal1996Papatheodoridisetal2001vanZonneveldetal2004Lineta
13、l2005Improvedclinicaloutcomeswithlamivudinelong-termviralsuppressionDiMarcoetal2004Liawetal2004Papatheodoridisetal2005Decreasedclinicalevents,improvedChild-Pughscores,decreasedHCCinpatientswithadvancedliverdiseasetreatedwithlamivudineLiawetal2004Improvedvirological,biochemical,andclinicalparametersi
14、nlamivudine-resistantpatientswithdecompensatedcirrhosistreatedwithadefovirSchiffetal20041415KeyRoleofHBVDNAinOn-TreatmentManagementi.TimingandmagnitudeofHBVDNAsuppressionRapidandProfoundHBVSuppression:aCriticalGoalofTherapyOutcomesPrimarygoaloftreatmentDelayinprogressiontocirrhosisandHCCImprovedsurv
15、ivalReducedresistanceIncreasedseroconversionImprovedliverhistologyNormalisedalanineaminotransferase(ALT)levelsSustainedsuppressionofHBVreplicationtothelowestpossiblelevelFontana2003;Gauthieretal1999;Keeffeetal2006;Liawetal2004;Liawetal2005;Mommeja-Marinetal2003;Niederauetal1996;Yuenetal200116Patient
16、swithHBVDNA20,000copies/mLat72weeks(%)SerumHBVDNAlevelat12weeks,copies/mLHBeAg-negativepatients(n=176)treatedwithpeg-interferonalfa-2afor48weeksP0.001Farcietal2005ViralSuppressionwithPeg-Interferonalfa-2aAssociationwithsubsequentHBVDNAresponse17Profound,EarlyViralSuppressionWeek24viralloadand2-yearo
17、utcomeswithtelbivudineandlamivudineQL=quantificationlimit(polymerasechainreaction(PCR)-undetectableat4logQL3003log34log4logTelbivudineLamivudine203 14657638379107 165178 15718201624102018Profound,EarlyViralSuppressionWeek24viralloadand1-yearoutcomeswithentecavirHBVDNAatweek24,copies/mLPCR-negativeat
18、week48,%HBeAg-positiveHBeAg-negative4004003log35log5log4004003log35log5log153/19528/3447/1186/15240/24720/2132/381/4BMSEntecavirAVDACBriefingDocument200519HBeAgseroconversionoccurredonlyinthisgroup468102Baseline81624324048566472WeeksMedianHBVDNA,log10copies/mLMedian104(n=11)Median5log1024HBeAglossLi
19、verinflammationandfibrosisHBeAg-positiveHBeAg-negativeReduceserumHBVDNANormalALTPCRnegativeAnti-HBeAgsero-conversionHBsAglossReduceserumHBVDNANormalALTPCRnegativeHBsAglossGoalsofHBVtherapya)Preventcirrhosis,liverfailureandHCCb)ImprovesurvivalSignpostSignpostEarlyViralSuppressionCanBeaSignpostforFutu
20、reTherapeuticResponseStartRx.2526On-TreatmentRoadmapConceptPotentialFoundationforBuildingaCHBTherapeuticRoadmapOn-treatnentearlyvirologicalresponsemonitoringCanhelptoidentifysuboptimalrespondersProvidesopportunitiestomodifytreatmenttoenhanceantiviralefficacyCanhelpsupportindividualisedtreatmentmapsH
21、asthepotentialtoimprovelong-termoutcomesResponsemarkersactassignpostsforclinicalmanagementChosentherapyiseffectiveandwelltoleratedAdditionalinterventionsrequired27UnresolvedquestionsWhatIsthebeston-treatmentmarker?When Isthebesttimingfordecisionpoints?WhatCut-offlevelforon-treatmentdecisions?Which T
22、ypeofinitial/add-ontherapy?ExpertpanelconvenedtoevaluateevidenceanddeveloptreatmentrecommendationsReportofanInternationalWorkshop:RoadmapforManagementofPatientsReceivingOralTherapyforChronicHepatitisBKeeffeEBetal.Clinical Gastroenterology and Hepatology2007ProposedNewTreatmentAlgorithmforCHBRecentex
23、pertpanelandRoadmappublicationKeeffeetal200728Starttreatment1log10copies/mLdecreasefrombaseline:primaryresponseRoadmapConceptManagementalgorithmaccordingto12-weekvirologicresponseContinue1log10copies/mLdecreasefrombaseline:primaryfailureNon-compliantCompliantCounselChangeTxWeek12:assessmentforprimar
24、ynon-responseKeeffeetal200729StarttreatmentRoadmapConceptOn-treatmentresponsesCompleteresponsePCRnegativePartialresponse602000IU/mLor3002000IU/mLor10,000copies/mLWeek12:assessmentforprimarynon-responseWeek24:earlypredictorsofefficacyKeeffeetal2007Definedas300copies/mL30RoadmapConceptManagementalgori
25、thmforcompleteresponseat24weeksCompleteresponsePCRnegativeContinueMonitor6-monthlyDefinitionofcompleteresponse:PCRnegative(300copies/mL)Intervalformonitoringcanbeprolongedtoevery6monthsInpatientswithmoreadvanceddisease,monitoringevery3monthsormorefrequentlyWeek24:earlypredictorsofefficacyKeeffeetal2
26、007Definedas300copies/mL31RoadmapConceptManagementalgorithmforpartialresponseat24weeksWeek24:earlypredictorsofefficacyKeeffeetal2007Partialresponse602000IU/mLor30010,000copies/mLAddanotherdrugwithoutcross-resistanceorcontinueMonitor3-monthly32Inadequateresponse2000IU/mLor10,000copies/mLAdaptregimenC
27、ompleteresponsePartialresponseInadequateresponseRoadmapConceptManagementalgorithmforinadequateresponseat24weeksWeek24:earlypredictorsofefficacyKeeffeetal2007Definedas300copies/mL33HBVRoadmapProposal:MonitoringMonitorevery3monthsIfpatientachievescompleteresponseby48weeks,followmonitoringrecommendatio
28、n(6-monthly)Ifpatientshowscontinuousdeclineupto48weeks,butstillhashigherviralloadthanacompleteresponder,continuetomonitorevery3monthsIfpatientshowsanincreaseorplateauingofvirallevel,theyshouldbetreatedbasedonroadmaprecommendationforinadequateornon-responderInpatientswithmoreadvanceddisease,morefrequ
29、entmonitoringmaybeindicatedKeeffeetal200734SummaryandConclusionsImportanceofearlymonitoringofvirologicresponsetotherapyEarlyandsustainedviralsuppressionhasbeenassociatedwithpreventionofdiseaseprogressionHBVDNAisacriticalsignpostintheon-treatmentmanagementofCHBOn-treatmentmanagementoffersopportunitie
30、stooptimisetreatmentresponseEssentialtoidentifysuboptimalresponsesModifymanagementtoenhanceantiviralefficacyPotentialtoimprovelong-termoutcomes3536Howshouldtheroadmapbeappliedtotelbivudine?36慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）3737ConclusionfromReportofanInternationalWorkshop:RoadmapforManagementofPatient
31、sReceivingOralTherapyforChronicHepatitisBEarly monitoring of the virologic response to therapy in chronic hepatitis B treated with oral nucleos(t)ides is essentialUse of this roadmap should permit improved individualized on-treatment management designed to enhance long-term patient outcomes1.KeeffeE
32、B,ZeuzemS,KoffRS,DieterichDT,Esteban-MurR,GaneE,JacobsonIM,LimSG,NaoumovNN,MarcellinP,PiratvisuthT,ZoulimF.ClinGastroenterolHepatol.Inpress.慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）3838Adaptedform:KeeffeEB,ZeuzemS,KoffRS,DieterichDT,Esteban-MurR,GaneE,JacobsonIM,LimSG,NaoumovNN,MarcellinP,PiratvisuthT,ZoulimF.
33、ClinGastroenterolHepatol.Inpress.StartTelbivudineEarlyVirologicResponseEfficacyatWeek24PCRNegativePCRNegative(300copies/mL)(1010，000copies/mL000copies/mLAssessmentofPrimaryResponseatweek12MaintainTelbivudineMaintainTelbivudineHowMaytheHBVTreatmentRoadmapbeAppliedtoTelbivudineTreatment?慢性乙型肝炎患者管理（英文版
34、）慢性乙型肝炎患者管理（英文版）3939ViralLoadAchievedbyWeek24:Telbivudinevs.LamivudineDiBisceglieA,etal.PresentedatAASLD20064LogHBeAgPositiveHBeAgPositiveHBeAgNegativeHBeAgNegative* P 0.05慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）4040TelbivudineIsAGoodOptionforTherapyforHBeAg-PositivePatients49%49% ofTelbivudineTreatedPatients
35、ofTelbivudineTreatedPatientsAchievePCRNegativity(300copies/mL)AchievePCRNegativity(300copies/mL)atWeek24atWeek2486%86% PCRNegativePCRNegativeWeek104Week10449%49% SeroconversionSeroconversionWeek104Week1042%2% ResistanceResistanceWeek92Week92BaselineALT2xULNN=55885%85% ALTNormalizationALTNormalizatio
36、nWeek104Week104慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）4141TelbivudineIsAGoodOptionforTherapyforHBeAg-NegativePatients80%80% ofTelbivudineTreatedPatientsofTelbivudineTreatedPatientsAchievePCRNegativity(300copies/mL)AchievePCRNegativity(300copies/mL)atWeek24atWeek2488%88% PCRNegativePCRNegativeWeek104Week104N=
37、78/86N=78/862%2% ResistanceatResistanceat92weeks92weeks49%49% SeroconversionSeroconversionWeek104Week104Alltelbivudine-treatedHBeAg-NegativePatientsN=588慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）4242StartTelbivudineEarlyVirologicResponseEfficacyatWeek24HBVDNAHBVDNAPCRNegativePCRNegative(300copies/mL)(300copies/
38、mL)HBVDNAHBVDNA3001010，000copies/mL000copies/mLMaintainTelbivudineWeek52-MonitorHBVDNAcloselyHowMaytheHBVTreatmentRoadmapbeAppliedtoTelbivudineTreatment?IfPCRNegativeIfPCRNegativeMaintainTelbivudineMonotherapyMaintainTelbivudineMonotherapyIfPCRPositiverevisetreatmentstrategyAdaptedform:KeeffeEB,Zeuz
39、emS,KoffRS,DieterichDT,Esteban-MurR,GaneE,JacobsonIM,LimSG,NaoumovNN,MarcellinP,PiratvisuthT,ZoulimF.ClinGastroenterolHepatol.Inpress.慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）4343StartTelbivudineEarlyVirologicResponseEfficacyatWeek24PCRNegativePCRNegative(300copies/mL)(300copies/mL)HBVDNAHBVDNA30010,000copies/
40、mLAssessmentofPrimaryResponseatweek12HowMaytheHBVTreatmentRoadmapbeAppliedtoTelbivudineTreatment?RevisetreatmentstrategyAdaptedform:KeeffeEB,ZeuzemS,KoffRS,DieterichDT,Esteban-MurR,GaneE,JacobsonIM,LimSG,NaoumovNN,MarcellinP,PiratvisuthT,ZoulimF.ClinGastroenterolHepatol.Inpress.慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）4444慢性乙型肝炎患者管理（英文版）慢性乙型肝炎患者管理（英文版）
